These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2563233)

  • 61. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
    Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients.
    Chouinard G; Annable L; Ross-Chouinard A
    Psychopharmacol Bull; 1986; 22(3):891-6. PubMed ID: 2879310
    [No Abstract]   [Full Text] [Related]  

  • 63. A depot neuroleptic withdrawal study neurological effects.
    Wistedt B; Wiles D; Jørgensen A
    Psychopharmacology (Berl); 1983; 80(2):101-5. PubMed ID: 6136059
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures.
    Gardos G; Cole JO; Rapkin RM; LaBrie RA; Baquelod E; Moore P; Sovner R; Doyle J
    Arch Gen Psychiatry; 1984 Nov; 41(11):1030-5. PubMed ID: 6149737
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects.
    Rao ML; Gross G; Strebel B; Bräunig P; Huber G; Klosterkötter J
    Psychiatry Res; 1990 Dec; 34(3):243-57. PubMed ID: 1981623
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tardive dyskinesia and the behavioral consequences of chronic neuroleptic treatment.
    Gualtieri CT; Guimond M
    Dev Med Child Neurol; 1981 Apr; 23(2):255-9. PubMed ID: 6111511
    [No Abstract]   [Full Text] [Related]  

  • 68. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D
    Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels.
    Baron JC; Martinot JL; Cambon H; Boulenger JP; Poirier MF; Caillard V; Blin J; Huret JD; Loc'h C; Maziere B
    Psychopharmacology (Berl); 1989; 99(4):463-72. PubMed ID: 2574481
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances.
    Tenback DE; van Harten PN; Slooff CJ; van Os J;
    Neuropsychopharmacology; 2006 Aug; 31(8):1832-7. PubMed ID: 16482082
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tardive dyskinesia. Pathophysiological mechanisms and clinical trials.
    Gerlach J
    Encephale; 1988 Sep; 14 Spec No():227-32. PubMed ID: 2905651
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Eur J Pharmacol; 1980 May; 63(2-3):145-57. PubMed ID: 6103814
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.
    Bagdy G; Perényi A; Frecska E; Révai K; Papp Z; Fekete MI; Arató M
    Psychopharmacology (Berl); 1985; 85(1):62-4. PubMed ID: 2580329
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Growth-hormone release and the tardive dyskinesia of neuroleptic withdrawal.
    Brown WA; Laughren TP
    Lancet; 1980 Feb; 1(8162):259. PubMed ID: 6101707
    [No Abstract]   [Full Text] [Related]  

  • 75. Prediction of relapse in schizophrenia.
    Lieberman JA; Kane JM; Sarantakos S; Gadaleta D; Woerner M; Alvir J; Ramos-Lorenzi J
    Arch Gen Psychiatry; 1987 Jul; 44(7):597-603. PubMed ID: 2886110
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A longitudinal study of EEG sleep in schizophrenia.
    Keshavan MS; Reynolds CF; Miewald JM; Montrose DM
    Psychiatry Res; 1996 Jan; 59(3):203-11. PubMed ID: 8930026
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Respiratory dysrhythmias in patients with tardive dyskinesia.
    Wilcox PG; Bassett A; Jones B; Fleetham JA
    Chest; 1994 Jan; 105(1):203-7. PubMed ID: 7903923
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia.
    Diamond BI; Borison RL
    Psychopharmacol Bull; 1986; 22(3):900-5. PubMed ID: 2879312
    [No Abstract]   [Full Text] [Related]  

  • 79. A neuroendocrine study of supersensitivity in tardive dyskinesia.
    Tamminga CA; Smith RC; Pandey G; Frohman LA; Davis JM
    Arch Gen Psychiatry; 1977 Oct; 34(10):1199-203. PubMed ID: 911219
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Striatal dopamine D2 receptors in tardive dyskinesia: PET study.
    Blin J; Baron JC; Cambon H; Bonnet AM; Dubois B; Loc'h C; Mazière B; Agid Y
    J Neurol Neurosurg Psychiatry; 1989 Nov; 52(11):1248-52. PubMed ID: 2574230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.